Erratum PDF Download Consensus statement on the treatment of transplant-eligible patients with newly diagnosed multiple myeloma in New Zealand Nicole Chien, Ken Romeril, Bart Baker, Hugh Goodman, Henry Chan, on behalf of the Myeloma Interest Group Published: 18 December 2020 (Vol 133 No 1527) In Table 1, the recommended dosage of Bortezomib in the VTD induction regimen was incorrectly reported as 1.3mg/m2. The correct recommended dosage is 1.5mg/m2. This error was resolved online and in the PDF on 13 January 2021. Summary